Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions

Costa, Ricardo; Abizaid, Alexandre; Mehran, Roxana; Schöfer, Joachim; Schuler, Gerhard; Hauptmann, Karl E.; Magalhães, Marco A.; Parise, Helen; Grube, Eberhard

doi:10.1016/j.jcin.2015.09.008

Cited by 71 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher rates of cardiac death and stent thrombosis often occur early in patients presenting with ST‐elevation myocardial infarction (STEMI) and late complications are more often seen in non‐ST‐elevation myocardial infarction (NSTEMI) . To improve clinical outcomes in patients presenting with ACS, novel stent technologies have been developed to target these complications after PCI, such as absorbable polymer stents (Mistent, Micell Technologies) , polymer‐free stents (biolimus stent, BioFreedom, Biosensor) , and the dual‐therapy stent (COMBO, OrbusNeich Medical) .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome

Kalkman

Menown

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome

Kalkman

Menown

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Notably, at 4 months, there was a significantly lower rate of lumen loss with the DCS than PES. The results demonstrated no inferiority to PES in the rate of lumen loss, a subclass of neointimal hyperplasia (Costa et al 2016). The use of nano-coatings on stents is being trialled currently in the United States: The COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention trial is ongoing and aims to investigate if the COBRA PzF stent with a polyzene-F nano-coating can successfully reduce bleeding compared to DES, through reducing the duration of oral anticoagulation therapy to 14 days, rather than the current 6 months, in patients undergoing PCI (US National Library of Medicine 2018).…”

Section: Nano-coated Stentsmentioning

confidence: 79%

The use of nanotechnology in cardiovascular disease

2018

View full text Add to dashboard Cite

Cardiovascular diseases claim a number of lives globally; many of which are preventable. With the increase in diets that consist of high saturated fat, salt, and sugar, people often living sedentary lifestyles, and a rise in cases of obesity, the incidence of cardiovascular disease is increasing. These contributing factors, coupled with more advanced methods of diagnosis, have delivered statistics that clearly show that there is a rising trend in the prevalence of cardiovascular disease. Treatment for cardiovascular diseases is limited currently to oral medicines or invasive surgery. There is a huge gap in this area of medicine for novel therapeutics for improved patient outcomes. Nanotechnology may provide a solution to more effective treatment of disease, with better prognoses and a reduced side effect profile. This review will explore for potential solutions to the limited pharmacological therapies currently on the market and the future that lies ahead for the place of nanotechnology within cardiovascular medicine.

show abstract

“…After duplicate references were removed, we retrieved 1026 potentially relevant articles. In the present meta-analysis, we included 13 RCTs [ [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] ] consisting of 8021 patients with coronary artery disease who were randomized to receive PCI with either PF-DES (n = 4545) or DP-DES (n = 3476). Table 1 outlines the study characteristics of the included trials.…”

Section: Resultsmentioning

confidence: 99%

Polymer-free versus durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis

Way

Kritharides

et al. 2019

Annals of Medicine and Surgery

View full text Add to dashboard Cite

BackgroundPolymer-free drug-eluting stents (PF-DES) were introduced with the aim of reducing the risk of stent thrombosis associated with durable polymer drug-eluting stents (DP-DES). The comparison of safety and efficacy profiles between these two stent platforms remains unclear.Materials and methodsWe conducted electronic database searches for randomized controlled trials (RCTs) comparing patients treated with either PF-DES or DP-DES. Outcomes included definite or probable stent thrombosis (ST), myocardial infarction (MI), cardiac death, all-cause death, target lesion revascularization (TLR), and target vessel revascularization (TVR). A random-effects model was used to derive risk ratios (RRs) with 95% confidence intervals (CIs). Subgroup analyses based on different variables were also performed. After screening a total of 1026 articles, the present meta-analysis included 13 RCTs comprising 8021 patients.ResultsNo significant differences were found for the risks of definite or probable ST (RR, 0.94; 95% CI, 0.62–1.43; P = 0.77), MI (RR, 1.06; 95% CI, 0.85–1.33; P = 0.61), cardiac death (RR, 0.98; 95% CI, 0.80–1.21; P = 0.88), all-cause death (RR, 0.87; 95% CI, 0.76–1.00; P = 0.06), TLR (RR, 1.12; 95% CI, 0.94–1.33; P = 0.22), and TVR (RR, 1.18; 95% CI, 0.87–1.61; P = 0.29). Similarly, no significant differences were found for all outcomes regardless of anti-proliferative drug, except for an increased risk of TLR for polymer-free paclitaxel-eluting stents compared with DP-DES (RR, 2.32, 95% CI, 1.30–4.14; P = 0.005).ConclusionsOur findings showed that PF-DES and DP-DES confer equivalent safety and efficacy profiles, with similar rates of stent thrombosis.

show abstract

Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions

Cited by 71 publications

References 29 publications

Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome

Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome

The use of nanotechnology in cardiovascular disease

Polymer-free versus durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis

Contact Info

Product

Resources

About